Regression of choroidal metastasis from breast carcinoma with palbociclib

Regression of choroidal metastasis from breast carcinoma with palbociclib

Abstract Background Uveal metastasis is reported to be the most common intraocular malignancy. The most common site of origin of ocular metastases in females is the breast. In some cases, uveal metastatic lesions respond to systemic chemotherapy. We report a case of a patient who developed choroidal...

Full description

Bibliographic Details
Main Authors:	Shweta Parakh, Shrutanjoy Das, Shrey Maheshwari, Vinita Gupta, Gaurav Luthra, Saurabh Luthra
Format:	Article
Language:	English
Published:	BMC 2022-08-01
Series:	International Journal of Retina and Vitreous
Subjects:	Choroidal metastasis Breast carcinoma Palbociclib Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor Palliative chemotherapy
Online Access:	https://doi.org/10.1186/s40942-022-00398-w

Similar Items

Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer
by: ZHENG Fangchao, et al.
Published: (2022-07-01)

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
by: Atakan Demir, et al.
Published: (2020-03-01)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer Cells
by: Lilibeth Lanceta, et al.
Published: (2020-04-01)

Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
by: Yeonhong Lee, et al.
Published: (2023-05-01)

Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma
by: David S. Shulman, et al.
Published: (2023-07-01)

Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy
by: Nadiia Lypova, et al.
Published: (2019-05-01)

Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials
by: Linghong Guo, et al.
Published: (2019-04-01)

FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells
by: Qiong Cheng, et al.
Published: (2021-11-01)

HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study
by: Francesca Carlino, et al.
Published: (2022-10-01)

Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells
by: Gregory T. Gallanis, et al.
Published: (2023-03-01)

Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy
by: Claudia Arndt, et al.
Published: (2023-02-01)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
by: Eric Raspé, et al.
Published: (2017-08-01)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
by: Zhimin Zhu, et al.
Published: (2023-07-01)

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan
by: Masataka Sawaki, et al.
Published: (2023-08-01)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
by: Zvonimir Mlinarić, et al.
Published: (2022-11-01)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
by: Lu Turković, et al.
Published: (2022-05-01)

3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor
by: James L. Tatum, et al.
Published: (2022-08-01)

CDK6 is activated by the atypical cyclin I to promote E2F‐mediated gene expression and cancer cell proliferation
by: Eva Quandt, et al.
Published: (2023-07-01)

The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers
by: Ayat Lashen, et al.
Published: (2024-04-01)

On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
by: Chang Gon Kim, et al.
Published: (2023-01-01)

Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
by: Shan Gao, et al.
Published: (2023-07-01)

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
by: Hasan Çağrı Yıldırım, et al.
Published: (2022-12-01)

The Role of Cyclin-Dependent Kinases (CDK) 4/6 in the Ovarian Tissue and the Possible Effects of Their Exogenous Inhibition
by: Graziana Scavone, et al.
Published: (2023-10-01)

Palbociclib Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells via RB-Independent STAT3 Phosphorylation
by: Wenjing Xiang, et al.
Published: (2022-08-01)

Commentary: locating the restriction point
by: Robert F. Brooks
Published: (2023-02-01)

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
by: Carole Bandiera, et al.
Published: (2023-01-01)

The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
by: Inês Gomes, et al.
Published: (2023-10-01)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
by: Emanuel Raschi, et al.
Published: (2021-04-01)

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
by: Diana Malarikova, et al.
Published: (2024-03-01)

Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania
by: Adina Turcu-Stiolica, et al.
Published: (2024-02-01)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
by: Hanxiao Xu, et al.
Published: (2017-04-01)

Conjugation of Palbociclib with MHI-148 Has an Increased Cytotoxic Effect for Breast Cancer Cells and an Altered Mechanism of Action
by: Peter Jaein Choi, et al.
Published: (2022-01-01)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
by: Lubaid Saleh, et al.
Published: (2023-04-01)

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
by: Mónica Cejuela, et al.
Published: (2023-05-01)

HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma
by: Zhipeng Li, et al.
Published: (2023-03-01)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
by: Qiong Qin, et al.
Published: (2020-09-01)

The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study
by: Nour Hisham Al-Ziftawi, et al.
Published: (2023-12-01)

Targeting CDK4/6 for Anticancer Therapy
by: Jiating Qi, et al.
Published: (2022-03-01)

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
by: Naiba Nabieva, et al.
Published: (2023-03-01)